Otonomy closes financing led by Novo Ventures and RiverVest
Otonomy, a biopharmaceutical company developing drug therapies for disorders of the inner and middle ear, has closed a USD38.5m series B financing co-led by Novo Ventures and RiverVest Venture Partners and joined by Domain Associates and TPG Biotech. This financing is incremental to the USD10m series A closed with Avalon


